Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene.

International journal of clinical oncology - 1 Apr 2009

Nishida Toshirou, Takahashi Tsuyoshi, Nishitani Akiko, Doi Toshihiko, Shirao Kuniaki, Komatsu Yoshito, Nakajima Kiyokazu, Hirota Seiichi

Abstract excerpt

BACKGROUND: Although sunitinib malate has shown significant clinical effect on imatinib-resistant gastrointestinal stromal tumors, with acceptable tolerability and improved prognosis for the patients, the mechanism of resistance to the drug is still under investigation. METHODS: We analyzed findings in 8 patients (seven men and one woman, median age, 59 years) out of 17 patients with imatinib-resistant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Triphosphate
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Stromal Tumors

Share to Indoles

Share to Proto-Oncogene Proteins c-kit

Share to Pyrroles

Share to Receptor, Platelet-Derived Growth Factor alpha

Share to Sunitinib

Source

Identifiers

PMID: 19390946
DOI: 10.1007/s10147-008-0822-y

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene.PMID 19390946Read ↗

Clinical impact of primary and secondary KIT mutations on the efficacy of molecular-targeted therapies in gastrointestinal stromal tumors.Semantic proximity Read ↗

Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.Semantic proximity Read ↗

Treatment of gastrointestinal stromal tumor after imatinib and sunitinib.Semantic proximity Read ↗

Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance.Semantic proximity Read ↗

KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.Semantic proximity Read ↗

Therapeutic targeting of c-KIT in cancer.Semantic proximity Read ↗

Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.Semantic proximity Read ↗

KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape.Semantic proximity Read ↗

Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.Semantic proximity Read ↗

KIT mutations in GIST.Semantic proximity Read ↗

Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis.Semantic proximity Read ↗

Secondary mutations in the kinase domain of the <i> KIT</i> gene are predominant in imatinib‐resistant gastrointestinal stromal tumorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.